Brief: Synaptogenix Moves Forward With Clinical Development Plans For Bryostatin-1 As Treatment For Multiple Sclerosis

TAO Synergies

23/02/2022 14:18

Feb 23 (Reuters) - Synaptogenix Inc  SNPX.O :
    * SYNAPTOGENIX MOVES FORWARD WITH CLINICAL DEVELOPMENT PLANS
FOR
BRYOSTATIN-1 AS A TREATMENT FOR MULTIPLE SCLEROSIS
    * SYNAPTOGENIX INC - WILL COLLABORATE WITH CLEVELAND CLINIC
THROUGH A NEW CONSULTING AGREEMENT

Source text for Eikon:  ID:nPn3HlX4a 
Further company coverage:  SNPX.O 

 ((Reuters.Briefs@thomsonreuters.com;))